Document is current
Any future updates will be listed below
-
Authors
Burnell, Matthew
Gentry-Maharaj, Aleksandra
Skates, Steven J.
Ryan, Andy
Karpinskyj, Chloe
Kalsi, Jatinderpal
Apostolidou, Sophia
Singh, Naveena
Dawnay, Anne
Woolas, Robert
Fallowfield, Lesley
Campbell, Stuart
McGuire, Alistair
Jacobs, Ian J.
Parmar, Mahesh
Menon, Usha http://orcid.org/0000-0003-3708-1732
-
Funding
Funding for this research was provided by:
Health Technology Assessment Programme (16/46/01)
The Eve Appeal (N/A)
Medical Research Council (G9901012 and G0801228)
Cancer Research UK (C1479/A2884)
UCLH Biomedical Research Centre (N/A)
- License Information
-
More Information
Article History
Received: 18 August 2020
Accepted: 11 February 2021
First Online: 1 March 2021
Ethics approval and consent to participate
: The initial study was approved by the UK North West Multicentre Research Ethics Committees (North West MREC 00/8/34) on 21 June 2000 with site-specific approval from the local regional ethics committees and the Caldicott guardians (data controllers) of the primary care trusts. The long-term follow-up amendment was approved on 24 January 2017 and the amended protocol including the new statistical plan was approved on 12 May 2020. All trial participants provided written informed consent.
: All authors have seen the final version of the manuscript and give their consent for publication.
: UM has stocks in Abcodia Ltd. awarded to her by UCL. SJS and IJJ are co-inventors of the Risk of Ovarian Cancer Algorithm (ROCA) that has been licensed to Abcodia Ltd. by Massachusetts General Hospital (MGH) and Queen Mary University of London (QMUL). IJJ has a financial interest in Abcodia Ltd as a shareholder and director. IJJ and SJS are entitled to royalty payments via MGH and QMUL from any commercial use of the ROCA. All other authors declare no competing interests.
